---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-049013"
form_type: "8-K"
ticker: null
cik: "0001435049"
company_name: "CHINOOK THERAPEUTICS, INC."
filed_at: "2023-02-24T23:59:59+00:00"
generated_at: "2026-06-19T00:38:47.749831+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Chinook Therapeutics amends bylaws to align with universal proxy rules and DGCL updates

## Summary
- Amended bylaws to comply with SEC universal proxy rules (Rule 14a-19) and recent DGCL changes.
- Revised advance notice provisions: additional disclosures, nominee limits, and interview requirements.
- Added exclusive forum provision designating Delaware Court of Chancery for certain disputes.
- Updated meeting conduct rules, including proxy card color requirement and electronic notice.
- Added emergency bylaw provision for director quorum during crises.

## SEC filing metadata
- accession: 0001193125-23-049013
- form_type: 8-K
- cik: 0001435049
- company_name: CHINOOK THERAPEUTICS, INC.
- filed_at: 2023-02-24T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1435049/000119312523049013/0001193125-23-049013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1435049/000119312523049013/d463440d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-049013
- JSON: https://secwatch.observer/filing/0001193125-23-049013.json
- Plain text: https://secwatch.observer/filing/0001193125-23-049013.txt

## Key facts
- Governance Changes
  CHINOOK THERAPEUTICS, INC.: Amended and restated bylaws to update provisions relating to stockholder meetings, advance notice, universal proxy rules, exclusive forum, and other conforming changes (effective 2023-02-23).
  - Change: bylaw amendment
  - Effective: 2023-02-23
  source text: On February 23, 2023, in connection with the effectiveness of new Securities and Exchange Commission rules regarding universal proxy cards, certain recent changes to the Delaware General Corporation Law (the “ DGCL ”), and a periodic review of the bylaws of Chinook Therapeutics, Inc. (the “ Company ”), the Company’s board of directors (the “ Board ”) approved and adopted the Company’s amended and restated bylaws (the “ Amended and Restated Bylaws ”), which became immediately effective.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1435049/000119312523049013/0001193125-23-049013-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.